Streetbeat News

IMNM

Immunome, Inc.

https://immunome.com

Industry

Biotechnology

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Open

11.19

Mkt cap

618M

Volume

3.2M

High

11.19

P/E Ratio

-1.31

52-wk high

30.96

Low

9.63

Div yield

N/A

52-wk low

6.93

Immunome (NASDAQ:IMNM) reported Q2 earnings per share (EPS) of $(0.60), missing the analyst estimate of $(0.39) by 53.85%. Sales were $2.36M, also missing the estimate of $2.55M by 7.29%. Both EPS and sales showed significant declines compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:02 pm

Imunon has clarified that its correct ticker symbol is 'IMNN'.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 8:31 pm

Nectin Therapeutics has entered into a global, exclusive license agreement with Immunome, granting Immunome exclusive rights to a panel of antibodies targeting an undisclosed target. Immunome will handle research, development, manufacturing, and commercialization, while Nectin will receive an upfront payment, milestones, and royalties.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:41 am

In the past three months, four analysts have provided ratings for Immunome (NASDAQ:IMNM), ranging from bullish to bearish. The average 12-month price target is $29.75, with a high of $35.00 and a low of $24.00. Recent ratings include 'Overweight' from Piper Sandler and JP Morgan, 'Buy' from Guggenheim, and 'Outperform' from Wedbush. Immunome, a biopharmaceutical company, has faced a revenue decline of -56.47% and has a net margin of -12584.26%.

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 1:00 pm

Piper Sandler has initiated coverage on Immunome (NASDAQ:IMNM) with an Overweight rating and a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 9:58 am

Several notable insider trades were reported, including significant purchases by insiders at ProFrac Holding, Immunome, Globe Life, and Astrotech. These trades indicate confidence in the respective companies' prospects.

Portfolio Pulse from Avi Kapoor

May 22, 2024 | 1:09 pm

Immunome shares are trading higher following a Form4 filing that revealed President and CEO Clay Siegall purchased 100,000 shares at an average price of $13.88 per share.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 10:40 am

Immunome shares are trading higher following a Form4 filing that revealed President and CEO Clay Siegall purchased 100,000 shares at an average price of $13.88 per share.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 8:34 pm

In Tuesday's after-market session, several health care stocks experienced significant movements. Rezolute (RZLT) saw a 52.7% increase, Mustang Bio (MBIO) rose by 30.64%, and Qilian Intl Hldg Gr (QLI) increased by 14.77%. On the downside, Durect (DRRX) fell by 13.2%, Cingulate (CING) decreased by 10.1%, and Haemonetics (HAE) dropped by 8.79%.

Portfolio Pulse from Benzinga Insights

May 21, 2024 | 8:31 pm

Immunome's President and CEO, Clay B Siegall, has purchased 100,000 shares of the company's stock at $13.88 per share, as per a recent SEC Form 4 filing.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 8:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.